GlaxoSmithKline

🇬🇧United Kingdom

Country: 🇬🇧United Kingdom

Ownership: Public

Established: 1929-01-01

Employees: 70.2K

Market Cap: $90B

Website: http://www.gsk.com

Introduction: GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the Commercial Operations, and Research and Development segments. The Commercial Operations segment has three product groups of specialty medicines, vaccines, and general medicines. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Clinical Trials

Single Dose Safety Study for Compound to Treat Anemia in Patients With Renal Impairment

Phase 1

Completed

Conditions: Kidney Disease

Interventions: Drug: GSK1278863A
Drug: Placebo

First Posted Date: 2009-07-09

Last Posted Date: 2017-07-27

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 12

Registration Number: NCT00935831

Locations: 🇳🇿
GSK Investigational Site, Christchurch, New Zealand

Clinical Study to Assess the Pharmacokinetics, Safety and Tolerability of SRT2104 Administered to Normal Healthy Male Volunteers

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Placebo
Drug: SRT2104

First Posted Date: 2009-07-07

Last Posted Date: 2017-07-07

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 10

Registration Number: NCT00933062

Locations: 🇬🇧
GSK Investigational Site, Merthyr Tydfill, Glamorgan, United Kingdom

Study of Safety and Efficacy of a Sequential Regimen Consisting of Three Cycles of Fludarabine Followed by Tositumomab and Iodine I 131 Tositumomab

Phase 2

Completed

Conditions: Lymphoma, Non-Hodgkin

Interventions: Biological: Tositumomab and Iodine I 131 Tositumomab

First Posted Date: 2009-07-07

Last Posted Date: 2017-01-18

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 38

Registration Number: NCT00933335

Extension Study of the Efficacy of the GSK 580299 Vaccine in Japanese Women Vaccinated in the Primary NCT00316693 Study

Phase 3

Completed

Conditions: Infections, Papillomavirus

Interventions: Procedure: Liquid-based cytology (LBC) sampling
Procedure: Blood sampling

First Posted Date: 2009-06-29

Last Posted Date: 2016-10-20

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 752

Registration Number: NCT00929526

Locations: 🇯🇵
GSK Investigational Site, Tokyo, Japan

Immunogenicity & Safety Study of Fluviral® (2009 - 2010 Season) in Adults Aged 18 to 60 Years and Over 60 Years

Phase 3

Completed

Conditions: Influenza, Human

Interventions: Biological: Fluviral®

First Posted Date: 2009-06-29

Last Posted Date: 2020-11-09

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 110

Registration Number: NCT00929331

Locations: 🇨🇦
GSK Investigational Site, Sherbrooke, Quebec, Canada

A Repeat Dose Study With GSK1018921 to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics in Healthy Volunteers and Patients With Schizophrenia and to Evaluate Its Effect on PK of Midazolam.

Phase 1

Terminated

Conditions: Schizophrenia

Interventions: Drug: Glycine Transporter-1 inhibitor

First Posted Date: 2009-06-29

Last Posted Date: 2009-06-29

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 34

Registration Number: NCT00929370

Locations: 🇺🇸
GSK Investigational Site, Bellaire, Texas, United States

Study of Natural History of Human Papillomavirus (HPV) Infections in Adult Women With Recurrent Conizations in Norway

Terminated

Conditions: Infections, Papillomavirus

Interventions: Procedure: Cancer Registry of Norway (database)

First Posted Date: 2009-06-19

Last Posted Date: 2015-04-20

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 410

Registration Number: NCT00924794

Locations: 🇳🇴
GSK Investigational Site, Bergen, Norway

Relative Bioavailability Study in Healthy Subjects

Phase 1

Completed

Conditions: Infections, Bacterial

Interventions: Drug: GSK1322322

First Posted Date: 2009-06-19

Last Posted Date: 2017-06-26

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 20

Registration Number: NCT00924911

Locations: 🇺🇸
GSK Investigational Site, Buffalo, New York, United States

GSK BHR Study (Sont)

Phase 4

Completed

Conditions: Asthma

Interventions: Drug: Placebo
Drug: FP 100mcg
Drug: FSC 100/50mcg
Drug: FP 500mcg
Drug: FSC 250/50mcg
Drug: FP 250mcg
Drug: FSC 500/50mcg

First Posted Date: 2009-06-15

Last Posted Date: 2016-09-01

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 464

Registration Number: NCT00920543

Locations: 🇵🇷
GSK Investigational Site, Ponce, Puerto Rico

Clinical Study to Assess the Effects of SRT2104 and Prednisolone on Biomarkers in Blood in Healthy Volunteers

Phase 1

Completed

Conditions: Pulmonary Disease, Chronic Obstructive

Interventions: Drug: Placebo
Drug: 0.25g SRT2104
Drug: Prednisolone
Drug: 0.5g SRT2104
Drug: 1g SRT2104
Drug: 2g SRT2104

First Posted Date: 2009-06-15

Last Posted Date: 2017-07-07

Lead Sponsor: GlaxoSmithKline

Target Recruit Count: 20

Registration Number: NCT00920660

Locations: 🇬🇧
GSK Investigational Site, Merthyr Tydfill, Glamorgan, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy